JP2017525755A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525755A5
JP2017525755A5 JP2017519448A JP2017519448A JP2017525755A5 JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5 JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
linker
compound according
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017519448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/036414 external-priority patent/WO2015195904A1/en
Publication of JP2017525755A publication Critical patent/JP2017525755A/ja
Publication of JP2017525755A5 publication Critical patent/JP2017525755A5/ja
Pending legal-status Critical Current

Links

JP2017519448A 2014-06-20 2015-06-18 Her2抗体−薬物抱合体 Pending JP2017525755A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462014912P 2014-06-20 2014-06-20
US62/014,912 2014-06-20
US201462015661P 2014-06-23 2014-06-23
US62/015,661 2014-06-23
PCT/US2015/036414 WO2015195904A1 (en) 2014-06-20 2015-06-18 Her2 antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2017525755A JP2017525755A (ja) 2017-09-07
JP2017525755A5 true JP2017525755A5 (enExample) 2018-07-26

Family

ID=54936097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519448A Pending JP2017525755A (ja) 2014-06-20 2015-06-18 Her2抗体−薬物抱合体

Country Status (16)

Country Link
US (1) US20160051695A1 (enExample)
EP (1) EP3157560A4 (enExample)
JP (1) JP2017525755A (enExample)
KR (1) KR20170063507A (enExample)
CN (1) CN106659783A (enExample)
AU (1) AU2015277100A1 (enExample)
BR (1) BR112016029588A2 (enExample)
CA (1) CA2952834A1 (enExample)
IL (1) IL249626A0 (enExample)
MX (1) MX2016017117A (enExample)
PH (1) PH12016502509A1 (enExample)
RU (1) RU2017101331A (enExample)
SG (2) SG11201610468XA (enExample)
TW (1) TW201625315A (enExample)
WO (1) WO2015195904A1 (enExample)
ZA (1) ZA201700306B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
KR20150119848A (ko) 2012-12-21 2015-10-26 바이오얼라이언스 씨.브이. 친수성 자기-희생 링커 및 그것의 포합체
CN106661124A (zh) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
MD3313845T2 (ro) * 2015-06-29 2021-02-28 Immunogen Inc Conjugați cu anticorpi având cisteină modificată prin inginerie genetică
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3394082B1 (en) * 2015-12-21 2020-08-12 Pfizer Inc Purification of antibody drug conjugates using a sodium phosphate gradient
JP7078536B2 (ja) 2016-01-08 2022-05-31 アルトゥルバイオ, インコーポレイテッド 四価抗psgl-1抗体とその使用
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
SG11201907288RA (en) * 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
AU2018231832A1 (en) 2017-03-10 2019-08-08 Quiapeg Pharmaceuticals Ab Releasable conjugates
EP3638699A1 (en) * 2017-06-16 2020-04-22 Eli Lilly and Company Engineered antibody compounds and conjugates thereof
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
KR20220127380A (ko) * 2018-03-09 2022-09-19 퀴아펙 파마슈티칼스 에이비 방출가능한 항체 접합체
WO2020029982A1 (en) * 2018-08-08 2020-02-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant bifunctional protein targeting cd47 and her2
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
CA3134423A1 (en) * 2019-03-22 2020-10-01 The Regents Of The University Of California Compositions and methods for modification of target molecules
EP4114854A1 (en) * 2020-03-05 2023-01-11 UMC Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
CN112618726B (zh) * 2020-12-21 2022-11-11 江南大学 一种抗体缀合物、增强抗体分子免疫效应功能的方法
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
DK4601703T3 (da) 2023-04-18 2026-05-11 Astrazeneca Ab Konjugater omfattende spaltelige linkere
IL326995A (en) * 2023-09-11 2026-05-01 Catena Biosciences Inc Polypeptide conjugate compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434275A1 (en) * 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
WO2005101017A1 (en) * 2004-04-07 2005-10-27 Genentech, Inc. Mass spectrometry of antibody conjugates
CA2754531A1 (en) * 2009-03-06 2010-09-30 Seattle Genetics, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
CA2766405A1 (en) * 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2011130598A1 (en) * 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
CA2956934C (en) * 2010-04-21 2019-07-09 Syntarga B.V. Novel conjugates of cc-1065 analogs and bifunctional linkers
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
KR20150119848A (ko) * 2012-12-21 2015-10-26 바이오얼라이언스 씨.브이. 친수성 자기-희생 링커 및 그것의 포합체
CA2900755C (en) * 2013-02-08 2021-07-20 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MX368396B (es) * 2014-01-10 2019-10-01 Synthon Biopharmaceuticals Bv Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies

Similar Documents

Publication Publication Date Title
RU2017101331A (ru) Конъюгаты антитело к her2 - лекарственное средство
US12285491B2 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
JP2016508136A5 (enExample)
RU2017101662A (ru) Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения
JP7853711B2 (ja) チューブリシン類縁体と細胞結合分子との共役体の製剤
RU2015129800A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
KR102655301B1 (ko) 비스-링키지를 사용한 세포독성 약물의 접합
RU2017101681A (ru) Конъюгаты анти-cd22 антитело - лекарственное средство и способы их применения
AU2023248079A1 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
KR20240095316A (ko) Bcma 단일클론 항체 및 항체-약물 접합체
JP2017528418A5 (enExample)
JP2023530128A (ja) 細胞結合分子とカンプトテシン類縁体との共役体
JP2024535637A5 (enExample)
JP2024510435A (ja) 生体活性化合物の内部移行複合体からの選択的薬物放出
JP2024511360A (ja) 生体活性化合物の内部移行複合体からの選択的薬物放出
JP2012522513A5 (enExample)
JP2012522512A5 (enExample)
KR20210117302A (ko) 분지형 링커를 갖는 아마니타 독소의 접합체
JP2025508009A5 (enExample)
CN105073988A (zh) 抗cdh3人源化抗体、其药剂偶联物以及它们的用途
WO2020065408A1 (en) Sulfomaleimide-based linkers and corresponding conjugates
JP2025508779A5 (enExample)
CN117120098A (zh) 内化的生物活性化合物缀合物的选择性药物释放
CN117120097A (zh) 内化的生物活性化合物缀合物的选择性药物释放
JP2026508115A (ja) リンカー薬物、その抗体-薬物コンジュゲート、並びにそれらの調製方法及び使用